Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) presented real-world claims analysis data at the ISPOR 2026 conference, revealing the significant clinical and economic burden of fibromyalgia in U.S. adults. The findings, based on a retrospective analysis of over 261,000 adult fibromyalgia patients, highlight high rates of comorbidities, extensive healthcare resource utilization, and widespread reliance on multimodal treatment approaches. The data underscore the unmet need for more effective long-term treatment options as Tonix advances its planned commercial launch of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg), the first new treatment for fibromyalgia in more than 15 years.
The analysis found that more than 93% of fibromyalgia patients had at least one comorbidity, such as depression, anxiety, or chronic pain conditions. Insured patients incurred substantial annual healthcare costs, driven primarily by inpatient services, emergency department visits, and prescription medications. The study also showed that patients often use multiple therapies concurrently, including analgesics, antidepressants, and anticonvulsants, yet many continue to experience inadequate symptom control. These findings highlight the substantial disease burden and the need for improved therapeutic options.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA, the company’s recently approved flagship medicine, represents the first new treatment for fibromyalgia in over 15 years. The company’s CNS commercial infrastructure also supports its marketed products for acute migraine, including Zembrace SymTouch and Tosymra. Additionally, Tonix is evaluating TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder, and its pipeline includes TNX-2900 (Phase 2 ready for Prader-Willi syndrome) and immunology programs such as TNX-4800 (monoclonal antibody for Lyme disease prophylaxis) and TNX-1500 (CD40 ligand inhibitor for kidney transplant rejection).
The full press release is available at https://ibn.fm/yMppz. For more information on Tonix Pharmaceuticals, visit the company’s newsroom at https://ibn.fm/TNXP. Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.